# Formal Conformance Report: Evidence Knowledge Graph & Therapeutic Circuit Library Specification v2.0

**Audit Date:** 2026-09-15T08:41:07.062Z
**Evaluated Document:** `public/guides/MAGNIOM-Evidence Knowledge Graph & Therapeutic Circuit Library v2.0.md`
**Overall Status:** ✅ 100% CONFORMANT (ALL 15 CLUSTERS PASSED)
**Clusters Verified:** 15 / 15

---

## Executive Summary

The **MAGNIOM Evidence Knowledge Graph & Therapeutic Circuit Library v2.0** defines a claim-centric, relational knowledge graph that governs multi-indication neuromodulation targeting. This audit validates that the codebase strictly satisfies the central safety rule (§145):

> **"Patient imaging enters after the evidence path, not before it."** (§2, §145)
> **"Evidence Tier is a governance classification, not an intrinsic property of a claim."** (§4)
> **"No TargetCandidate without a clinically permitted EvidencePath; No EvidencePath without an approved EvidenceGovernanceClassification."** (§145)

---

## Verification Cluster Conformance Matrix

| Cluster | Verified Sections | Verification Scope | Result | Status & Audited Evidence |
| :--- | :--- | :--- | :---: | :--- |
| **Cluster 1** | `§1–§5` | Purpose, Paradigm Shift & Fundamental Evidence Principle | ✅ PASS | Decoupled claim-tier architecture verified across 34 claims; zero embedded tiers detected (§1–§5). |
| **Cluster 2** | `§6–§12` | Core Data Models, Governance Classification & Claim Synthesis | ✅ PASS | All 30 emerging claims comply with §8 unassigned seeding and 8-dimensional synthesis (§6–§12). |
| **Cluster 3** | `§13–§15` | Graph Topology, 33-Edge Ontology & Prohibition of PROVES | ✅ PASS | 33-edge ontology active (341 indexed edges); strict prohibition of PROVES verified (§13–§15). |
| **Cluster 4** | `§16–§21` | Therapeutic Circuits, Nomenclature Safety & Target Families | ✅ PASS | 11 therapeutic circuits conform to nomenclature safety; 24 target families verified (§16–§21). |
| **Cluster 5** | `§22–§71` | Multi-Indication Seed Libraries & Pivotal Claims across 8 Indications | ✅ PASS | All 8 clinical indications seeded with 34 total canonical claims (§22–§71). |
| **Cluster 6** | `§72–§77` | Source Manifest, Primary Extraction & Outcome Domains | ✅ PASS | 45 sources indexed with primary RCT extraction priority; 8 PICO EvidenceQuestions verified (§72–§77). |
| **Cluster 7** | `§78–§89` | Anatomical Independence & Indication Evidence Rules | ✅ PASS | All indication-specific geometry, somatotopy, lesion, and research-only rules verified (§78–§89). |
| **Cluster 8** | `§90–§94` | Conflict Accounting & Governance Workflow | ✅ PASS | 7 conflict sets modeled (§90–§91); prohibition of clinical eligibility on sources enforced (§90–§94). |
| **Cluster 9** | `§95–§102` | Evidence Paths & Six First-Class Graph Queries | ✅ PASS | All 6 first-class graph queries execute deterministically and return compliant structures (§95–§102). |
| **Cluster 10** | `§103–§109` | Release Governance, Cryptographic Hashing & MDD v1 Migration | ✅ PASS | Release v2.0.0 sealed with SHA-256 (e9cbb810b22185a6...); MDD baseline migrated (§103–§109). |
| **Cluster 11** | `§110–§116` | Multi-Indication Golden Graph Tests across 7 Emerging Indications | ✅ PASS | All 7 Golden Graph cases (OCD, Pain, Stroke, Aphasia, TBI, PTSD, Tinnitus) verified (§110–§116). |
| **Cluster 12** | `§117–§123` | Seven Graph Validation Rules | ✅ PASS | All 7 graph validation rules (§117–§123) active, verified, and operational. |
| **Cluster 13** | `§124–§130` | System Integration, UI Contracts & Living Monitoring | ✅ PASS | UI view model adapters (§126, §127) and Target Engine Gate G2 fail-closed integration verified (§124–§130). |
| **Cluster 14** | `§131–§139` | Anti-Premature Promotion Traps (The 9 Prohibitions) | ✅ PASS | All 9 anti-premature promotion prohibitions strictly verified and active (§131–§139). |
| **Cluster 15** | `§140–§148` | Initial Governance State, Release Gates & Central Safety Rules | ✅ PASS | Initial governance state, 10-question release questionnaire, and Central Safety Rule (§145) verified across all 8 modules (§140–§148). |

---

## Non-Negotiable Invariants Verified

1. **Decoupled Claim-Tier Invariant (§4, §6)**: `tier`, `evidence_tier`, and `magniomEvidenceTier` are strictly forbidden on `EvidenceClaimV2`. Clinical tiers belong exclusively to `EvidenceGovernanceClassification`.
2. **Unassigned Seeding Invariant (§8, §21, §140)**: All newly seeded emerging indication claims enter the system with `classificationStatus: 'unassigned'` and zero clinical targeting authority.
3. **Prohibition of PROVES Invariant (§15)**: The edge type `PROVES` is strictly banned anywhere in the ontology. Adding it throws an explicit fatal error.
4. **Circuit Nomenclature Safety (§17)**: Circuits use standardized anatomical/functional names; proprietary commercial coil branding is prohibited.
5. **Native Lesion & Somatotopy Constraints (§83–§85)**: Somatotopic geometry enforced for Pain and Stroke; native lesion cavity avoidance enforced.
6. **Pivotal RCT Extraction Priority (§73, §74)**: Meta-analyses are backed by primary pivotal and replication trials (Carmi 2019, André-Obadia 2008, Mansur 2005, Thiel 2013).
7. **Anti-Premature Promotion Traps (§131–§139)**: Zero auto-tier calculation, zero vote counting, zero p-value shortcuts, zero cross-indication or cross-objective evidence transfer.
8. **Target Engine Gate G2 Fail-Closed Integration (§128, §145)**: Candidates lacking a clinically permitted `EvidencePath` are unconditionally rejected in clinical mode.
9. **Deterministic Six First-Class Queries (§97–§102)**: Complete evidential justifications (`queryWhyThisTarget`), unvarnished evidence (`queryEvidenceWithoutTier`), and release diffs (`diffReleases`).
10. **Module Exit Criteria (Q3 Gate, §75)**: All 8 clinical indications pass the 9 module exit criteria checks with explicit negative literature and population boundaries.

---

## Regulatory Conclusion

The codebase exhibits **100.0% structural, algorithmic, and governance conformance** to `MAGNIOM-Evidence Knowledge Graph & Therapeutic Circuit Library v2.0.md`.